generalized anxiety disorder Archives

Representative image: Otsuka’s centanafadine Phase 3b results highlight the investigational ADHD treatment’s potential in adults with comorbid anxiety ahead of the FDA decision.

Could centanafadine reshape nonstimulant ADHD treatment after Otsuka’s Phase 3b success?

by Pallavi Madhiraju
June 27, 2026
0 Comments

Discover how Otsuka’s centanafadine Phase 3b ADHD data could shape FDA review and the nonstimulant treatment market. Read more.

Representative image: Definium Therapeutics’ $805 million public offering strengthens its ability to advance DT120 ODT after positive Phase 3 depression trial results, while regulatory and commercial execution remain the next major tests.

Pharma & Biotech

DT120 delivered a Phase 3 surprise. Can Definium Therapeutics turn $805m into a launch?

by Pallavi Madhiraju
June 26, 2026
0 Comments

Definium Therapeutics has used the strong market response to its DT120 ODT depression data to secure one of the largest recent biotechnology financings, giving the psychiatric drug developer substantial resources for additional trials, regulatory work and potential commercialisation.

A clinician monitors a supervised treatment session as Definium Therapeutics advances DT120, a single-dose investigational therapy for major depressive disorder, following positive Phase 3 results. Representative image.

Pharma & Biotech

Can Definium turn a 50% stock surge into an FDA path for single-dose depression therapy?

by Pallavi Madhiraju
June 23, 2026
0 Comments

DT120 produced a striking Phase 3 antidepressant effect after one supervised dose, but confirmation, functional unblinding, controlled-substance rules and treatment-site economics remain decisive.